kelch repeat and BTB domain containing 8Genealiases: TA-KRP · TAKRP
Q-omics provides the consensus-scored KBTBD8 profile across patient tissues and cancer cell-line models. KBTBD8 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, KBTBD8 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, KBTBD8 RNA expression shows 17,987 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where KBTBD8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KBTBD8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KBTBD8 survival associations across molecular data types. KBTBD8 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KBTBD8 RNA expression–survival associations across cancer types. High KBTBD8 expression shows unfavorable associations in LAML, KICH and LGG, but favorable associations in SKCM, LUAD and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for KBTBD8 RNA expression.
This table summarizes KBTBD8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KBTBD8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KBTBD8 shows lower tumor expression in LUSC, LUAD, BLCA and THCA and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher KBTBD8 RNA expression in tumor versus normal tissue (log2 FC = +0.488, t-test p < 0.001).
This table shows molecular features associated with KBTBD8 in patient tissues and cancer cell lines. In patient samples, KBTBD8 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KBTBD8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
